Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices 2707 

was determined to be complete on 

November 20, 2024. Under section 

1865(a)(2) of the Act and our regulations 

at § 488.5 (Application and reapplication procedures for national 

AOs), our review and evaluation of TJC 

will be conducted in accordance with, 

but not necessarily limited to, the 

following factors: 

• The equivalency of TJC’s standards 

for hospices as compared with CMS’ 

hospice CoPs. 

• TJC’s survey process to determine 

the following: 

++ The composition of the survey 

team, surveyor qualifications, and the 

ability of the organization to provide 

continuing surveyor training. 

++ The comparability of TJC’s 

processes to those of state agencies, 

including survey frequency, and the 

ability to investigate and respond 

appropriately to complaints against 

accredited facilities. 

++ TJC’s processes and procedures 

for monitoring hospices which are 

found out of compliance with TJC’s 

program requirements. These 

monitoring procedures are used only 

when TJC identifies noncompliance. If 

noncompliance is identified through 

validation reviews or complaint 

surveys, the SA monitors corrections as 

specified at § 488.9. 

++ TJC’s capacity to report 

deficiencies to the surveyed facilities 

and respond to the facility’s plan of 

correction in a timely manner. 

++ TJC’s capacity to provide CMS 

with electronic data and reports 

necessary for effective validation and 

assessment of the organization’s survey 

process. 

++ The adequacy of TJC’s staff and 

other resources, and its financial 

viability. 

++ TJC’s capacity to adequately fund 

required surveys. 

++ TJC’s policies with respect to 

whether surveys are announced or 

unannounced, to ensure that surveys are 

unannounced. 

++ TJC’s policies and procedures to 

avoid conflicts of interest, including the 

appearance of conflicts of interest, 

involving individuals who conduct 

surveys or participate in accreditation 

decisions. 

++ TJC’s agreement to provide CMS 

with a copy of the most current 

accreditation survey, together with any 

other information related to the survey 

as we may require (including corrective 

action plans). 

IV. Collection of Information 

Requirements 

This document does not impose 

information collection requirements, 

that is, reporting, recordkeeping or third 

party disclosure requirements. 

Consequently, there is no need for 

review by the Office of Management and 

Budget under the authority of the 

Paperwork Reduction Act of 1995 (44 

U.S.C. 3501 et seq.). 

V. Response to Comments 

Because of the large number of public 

comments we normally receive on 

Federal Register documents, we are not 

able to acknowledge or respond to them 

individually. We will consider all 

comments we receive by the date and 

time specified in the DATES section of 

this preamble, and, when we proceed 

with a subsequent document, we will 

respond to the comments in the 

preamble to that document. 

The Administrator of the Centers for 

Medicare & Medicaid Services (CMS), 

Chiquita Brooks-LaSure, having 

reviewed and approved this document, 

authorizes Vanessa Garcia, who is the 

Federal Register Liaison, to 

electronically sign this document for 

purposes of publication in the Federal 

Register. 

Vanessa Garcia, 

Federal Register Liaison, Centers for Medicare 

& Medicaid Services. 

[FR Doc. 2025–00448 Filed 1–10–25; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for Office of Management 

and Budget Review; Administration for 

Native Americans Project Outcome 

Assessment Survey (Office of 

Management and Budget #: 0970–0379) 

AGENCY: Administration for Native 

Americans, Administration for Children 

and Families, U.S. Department of Health 

and Human Services. 

ACTION: Request for public comments. 

SUMMARY: The Administration for 

Children and Families (ACF) is 

requesting a 3-year extension of the 

Administration for Native Americans 

Project Outcome Assessment Survey 

(OMB #: 0970–0379, expiration 6/30/ 

2025). The survey was revised based on 

a review by the Administration for 

Native Americans (ANA) and feedback 

from grantees, which identified some 

data elements that could be eliminated 

and areas that could be clarified. 

DATES: Comments due February 12, 

2025. OMB must make a decision about 

the collection of information between 30 

and 60 days after publication of this 

document in the Federal Register. 

Therefore, a comment is best assured of 

having its full effect if OMB receives it 

within 30 days of publication. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. You can also obtain 

copies of the proposed collection of 

information by emailing infocollection@

acf.hhs.gov. Identify all emailed 

requests by the title of the information 

collection. 

SUPPLEMENTARY INFORMATION: 

Description: The information 

collected by the Project Outcome 

Assessment Survey is needed for two 

main reasons—(1) to collect crucial 

information required to report on ANA’s 

established Government Performance 

and Results Act (GPRA) measures and 

(2) to properly abide by ANA’s 

congressionally mandated statute (42 

U.S.C. 2991 et seq.) found within the 

Native American Programs Act of 1974, 

as amended, which states that ANA will 

evaluate projects assisted through ANA 

grant dollars ‘‘including evaluations that 

describe and measure the impact of 

such projects, their effectiveness in 

achieving stated goals, their impact on 

related programs, and their structure 

and mechanisms for delivery of 

services.’’ The survey information is 

requested once at the end of a project 

grant period. The information collected 

with this survey will fulfill ANA’s 

statutory requirement and will also 

serve as an important planning and 

performance tool for ANA. 

There are minor revisions proposed to 

the survey to align with ANA’s current 

requirements of grant recipients and 

eliminate duplicative data elements. 

Respondents: Tribal Governments, 

Native American nonprofit 

organizations, and Tribal Colleges and 

Universities. 


ddrumheller on DSK120RN23PROD with NOTICES1
2708 Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden 

hours per 

response 

Annual 

burden 

hours 

ANA Project Outcome Assessment Survey .................................................................. 85 1 6 510 

Authority: 42 U.S.C. 2992. 

Mary C. Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2025–00490 Filed 1–10–25; 8:45 am] 

BILLING CODE 4184– 34–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Oncology 1-Basic 

Translational Integrated Review Group; 

Cancer Cell Biology Study Section 

Date: February 6–7, 2025. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Alyssa Diane Gregory, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, alyssa.gregory@nih.gov. 

Name of Committee: Biobehavioral and 

Behavioral Processes Integrated Review 

Group; Child Psychopathology and 

Developmental Disabilities Study Section. 

Date: February 10–12, 2025. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Karen Elizabeth Seymour, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1000–E, 

Bethesda, MD 20892, (301) 443–9485, 

karen.seymour@nih.gov. 

Name of Committee: Genes, Genomes, and 

Genetics Integrated Review Group; 

Maximizing Investigators’ Research Award— 

F Study Section. 

Date: February 10–11, 2025. 

Time: 10:00 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Brian Paul Chadwick, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–3586, chadwickbp@

csr.nih.gov. 

Name of Committee: Brain Disorders and 

Clinical Neuroscience, Integrated Review 

Group; Brain Injury and Neurovascular 

Pathologies Study Section. 

Date: February 10–11, 2025. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

6701 Rockledge Drive, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Alexander Yakovlev, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5206, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1254, yakovleva@csr.nih.gov. 

Name of Committee: Interdisciplinary 

Molecular Sciences and Training Integrated 

Review Group; Cellular and Molecular 

Technologies Study Section. 

Date: February 11–12, 2025. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Tatiana V. Cohen, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5213, 

Bethesda, MD 20892, 301–455–2364, 

tatiana.cohen@nih.gov. 

Name of Committee: Biological Chemistry 

and Macromolecular Biophysics Integrated 

Review Group; Macromolecular Structure 

and Function B Study Section. 

Date: February 11–12, 2025. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Alexei A. Yeliseev, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 443–0552, yeliseeva@

mail.nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology A Integrated Review Group; 

Pathogenic Eukaryotes Study Section. 

Date: February 11–12, 2025. 

Time: 9:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Jennifer Chien Villa, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, 301–496–5436, jennifer.villa@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: January 6, 2025. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2025–00458 Filed 1–10–25; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Statement of Delegation of Authority 

Notice is hereby given that I have 

delegated to the Director, National 

Institutes of Health (NIH), the authority 

vested in the Secretary of Health and 

Human Services under the Dr. 

Emmanuel Bilirakis and Honorable 

Jennifer Wexton National Plan to End 

Parkinson’s Act (Pub. L. 118–66) (Act). 

The Act amends Title III of the Public 

Health Service Act by adding section 

399OO, 42 U.S.C. 280n. The Act directs 

the Secretary to carry out a national 

project to prevent, diagnose, treat, and 

cure Parkinson’s, to be known as the 

National Parkinson’s Project, including 


ddrumheller on DSK120RN23PROD with NOTICES1

I I